AUS
NZ
UK
CA
USA
IND
Healt
Orthocell’s record revenue signals an expanding growth path
January 06, 2026 11:47 AM AEDT| By SamThis article explores how Orthocell (ASX:OCC) achieved record quarterly revenue, advanced international expansion, and strengthened commercial execution while building pathways across new healthcare markets.
Nanosonics (ASX:NAN) Shares Trade in Line With ASX 300 Index
January 05, 2026 09:35 PM AEDT| By SamNanosonics (ASX:NAN) provides automated infection control devices, emphasizing research and development, regulatory compliance, and operational deployment within the medical technology sector.
ASX 200 Today Small Cap Spotlight on Aroa Biosurgery and Sector Activity
January 05, 2026 06:10 PM AEDT| By SamHealthcare small-cap Aroa Biosurgery reflects sector diversification within the ASX landscape through medical technology operations and regulated product deployment.
Azer-cel Moves Imugene Forward in Next-Generation CAR-T Therapy
January 05, 2026 04:21 PM AEDT| By SamThis article explores how Imugene is advancing azer-cel, strengthening trial planning, expanding collaborations, and shaping new directions in CAR-T therapy while aligning with broader ASX healthcare and innovation themes.
CSL Shares: What Drove the Deep Slide and What It Means
January 05, 2026 12:31 PM AEDT| By SamThis article explores the wide-ranging factors that weighed on CSL shares, examining business fundamentals, division-level challenges, and broader market sentiment.
Actinogen’s ASX Move Signals Fresh Momentum for Local Biotech
January 02, 2026 04:40 PM AEDT| By Team Kalkine MediaActinogen Medical’s latest ASX disclosure highlights routine capital alignment, reinforcing transparency and governance within Australia’s biotech sector and offering context for readers following domestic equity developments.
Is ResMed CDI (ASX:RMD) Still Shaping Value For Investors?
December 31, 2025 08:23 PM AEDT| By SamResMed CDI explores opportunities through medical technology and digital care solutions while market participants assess value and long-term direction across healthcare and broader Australian equities.
Arovella moves IND toward first in human trial path
December 31, 2025 01:08 PM AEDT| By SamArovella Therapeutics (ASX:ALA) advances its IND submission for ALA-one-oh-one, outlining the pathway toward a first in human study for CD-nineteen-positive blood cancers and setting the groundwork for multi-region clinical activity.
Memphasys Share Quotation Update Signals Broader ASX Market Focus
December 31, 2025 11:44 AM AEDT| By SamMemphasys’ latest ASX share quotation highlights the importance of capital structure alignment, transparency, and steady market engagement within Australia’s evolving equity landscape.
Prescient Therapeutics Moves Forward Toward New Horizons Ahead
December 30, 2025 12:13 PM AEDT| By SamThe article explores how Prescient Therapeutics (ASX:PTX) advanced clinical development, strengthened regulatory positioning, and prepared for broader trial activity, setting the stage for the next phase of growth.
Why CLEO Diagnostics’ ASX Update Matters for Market Watchers
December 29, 2025 12:02 PM AEDT| By SamCLEO Diagnostics’ latest ASX update highlights how routine capital management aligns with transparency, liquidity, and short activity considerations across Australia’s diverse equity market.
Market Update: What CLEO’s New Share Quotation Signals for ASX Investors
December 29, 2025 11:55 AM AEDT| By SamCLEO Diagnostics’ quoted share expansion highlights disciplined capital management, reinforcing transparency and liquidity visibility within Australia’s healthcare innovation segment.
Memphasys CE Mark Approval Opens New European Pathways
December 29, 2025 11:45 AM AEDT| By SamMemphasys (ASX:MEM) steps forward with CE Mark approval for the Felix System, creating gateways to new markets and setting the foundation for broader global expansion.
CSL Limited Overview on ASX 300 With Market Context and Healthcare Developments
December 24, 2025 05:34 PM AEDT| By SamCSL Limited overview covering healthcare sector positioning, global operations, recent corporate context, and index inclusion within Australia’s equity market.
CSL’s Market Reset: What Its ASX 200 Journey Signals for Long-Term Investors
December 24, 2025 12:28 PM AEDT| By SamCSL’s recent market journey highlights shifting sentiment, resilient healthcare operations, and broader lessons about valuation and expectations within Australia’s leading equity indices.
Neurizon Therapeutics Strengthens ALS Trial Momentum
December 23, 2025 08:58 PM AEDT| By SamNeurizon Therapeutics strengthens its clinical development pathway through strategic funding, supporting ALS research progress within a global trial framework while reinforcing its position in the Australian healthcare market.
Actinogen’s ASX Move Signals a Fresh Chapter in Australian Biotech
December 23, 2025 04:48 PM AEDT| By SamActinogen Medical advances capital transparency through a new ASX quotation, reinforcing disciplined governance and supporting long-term innovation within Australia’s listed biotechnology sector.
Actinogen Medical Advances Market Access With New ASX Share Quotation
December 23, 2025 04:24 PM AEDT| By SamActinogen Medical’s ASX share quotation highlights how Australian listed companies manage capital structure updates within a transparent and regulated market environment.
Neurizon Therapeutics Advances ALS Research With New Capital
December 23, 2025 12:46 PM AEDT| By SamNeurizon Therapeutics advances its ALS clinical journey with new funding support, strengthening trial readiness and research momentum while remaining active within the ASX stock market ecosystem.
Dimerix Licensing Stability Signals Confidence After US Pharma Deal
December 22, 2025 12:55 PM AEDT| By SamThis article explores how Dimerix’s US licensing arrangement stays intact after a major pharmaceutical acquisition, outlining implications for drug development, global partnerships, and the broader ASX stock market landscape.
Advertise your brand on Kalkine Media